These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 27813430

  • 1. Fluzone® High-Dose Influenza Vaccine.
    Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP.
    Expert Rev Vaccines; 2016 Dec; 15(12):1495-1505. PubMed ID: 27813430
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
    DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK.
    N Engl J Med; 2014 Aug 14; 371(7):635-45. PubMed ID: 25119609
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
    Raviotta JM, Smith KJ, DePasse J, Brown ST, Shim E, Nowalk MP, Wateska A, France GS, Zimmerman RK.
    Vaccine; 2017 Oct 09; 35(42):5708-5713. PubMed ID: 28890196
    [Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK, QHD00013 Study Group.
    Vaccine; 2019 Sep 16; 37(39):5825-5834. PubMed ID: 31431411
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review.
    Colrat F, Thommes E, Largeron N, Alvarez FP.
    Vaccine; 2021 Mar 15; 39 Suppl 1():A42-A50. PubMed ID: 33518466
    [Abstract] [Full Text] [Related]

  • 7. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
    Chit A, Roiz J, Briquet B, Greenberg DP.
    Vaccine; 2015 Jan 29; 33(5):734-41. PubMed ID: 25444791
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis.
    Samson SI, Leventhal PS, Salamand C, Meng Y, Seet BT, Landolfi V, Greenberg D, Hollingsworth R.
    Expert Rev Vaccines; 2019 Mar 29; 18(3):295-308. PubMed ID: 30689467
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults.
    Chahine EB.
    Ann Pharmacother; 2021 Jan 29; 55(1):89-97. PubMed ID: 32578447
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V.
    Vaccine; 2014 May 01; 32(21):2507-17. PubMed ID: 24120672
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
    Boikos C, Fischer L, O'Brien D, Vasey J, Sylvester GC, Mansi JA.
    Clin Infect Dis; 2021 Sep 07; 73(5):816-823. PubMed ID: 33605977
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, Matassa V, Leong J.
    Vaccine; 2017 Apr 04; 35(15):1856-1864. PubMed ID: 28302411
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial.
    Schmader KE, Liu CK, Harrington T, Rountree W, Auerbach H, Walter EB, Barnett ED, Schlaudecker EP, Todd CA, Poniewierski M, Staat MA, Wodi P, Broder KR.
    JAMA Netw Open; 2021 Jan 04; 4(1):e2031266. PubMed ID: 33443580
    [Abstract] [Full Text] [Related]

  • 17. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19.
    Balasubramani GK, Choi WS, Nowalk MP, Zimmerman RK, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Jackson ML, Jackson LA, Chung JR, Spencer S, Fry AM, Patel M, Flannery B, US Flu VE Network Investigators.
    Vaccine; 2020 Sep 29; 38(42):6562-6569. PubMed ID: 32800465
    [Abstract] [Full Text] [Related]

  • 18. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
    Pillsbury AJ, Fathima P, Quinn HE, Cashman P, Blyth CC, Leeb A, Macartney KK.
    JAMA Netw Open; 2020 May 01; 3(5):e204079. PubMed ID: 32369177
    [Abstract] [Full Text] [Related]

  • 19. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model.
    Chit A, Roiz J, Aballea S.
    PLoS One; 2015 May 01; 10(7):e0133606. PubMed ID: 26222538
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
    Frey SE, Bernstein DI, Brady RC, Keitel WA, El Sahly H, Rouphael NG, Mulligan MJ, Atmar RL, Edupuganti S, Patel SM, Dickey M, Graham I, Anderson EL, Noah DL, Hill H, Wolff M, Belshe RB.
    Vaccine; 2015 Jan 01; 33(1):163-73. PubMed ID: 25444805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.